Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 42 clinical trials
Epidemiology and Pathophysiology of Parkinsonism in the Caribbeans

The primary aim of this study is to estimate the frequency and to characterize clinically atypical parkinsonism in the French West Indies and Guyana.

  • 0 views
  • 21 Jan, 2021
  • 2 locations
Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)

Opicapone (OPC) is a third generation catechol O methyltransferase (COMT) inhibitor (COMTi) developed by BIAL-Portela & C, S.A. It is approved as adjunctive therapy to preparations of L-DOPA

  • 0 views
  • 04 Aug, 2021
  • 1 location
Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy (RIVA-PSP)

-threatening situations and death occurs 6-9 years after disease onset. Apart from L-dopa which may transiently and inconsistently improve motor symptoms no effective symptomatic, disease-modifying or

parkinsonism
gaze palsy
donepezil
parkinson's disease
mini-mental state examination
  • 203 views
  • 09 Aug, 2022
  • 1 location
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients (AADC)

The overall objective of this study is to determine the safety and efficacy of AAV2-hAADC delivered to the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) in children with aromatic L-amino acid decarboxylase (AADC) deficiency.

  • 13 views
  • 21 Mar, 2022
  • 2 locations
Neurophysiologic Assessment of ET Patients Treated by Vim DBS

Essential tremor is a chronic and progressive neurological disease characterized by upper limb tremor. This is one of the most frequent movement disorders. Most of the time the disease worsens over the time, affecting patients' work abilities and in the most severe cases activities of daily living such as eating …

brain stimulation
limb tremor
neurological disorder
neurosurgery
  • 0 views
  • 06 Jun, 2022
  • 1 location
18F-DOPA II - PET Imaging Optimization

A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: Pediatric patients (less than 18 years

parkinson's disease
dementia
dopa
  • 8 views
  • 03 May, 2022
  • 1 location
[18F]F-DOPA Imaging in Patients With Autonomic Failure

these biomarkers may be related to the neurotransmitter dopamine (DA) and related changes in the substantia nigra (SN) and brainstem. [18F]F-DOPA is a radiolabeled substrate for aromatic amino acid

alpha-synuclein
demented
lewy body dementia
synucleinopathy
nervous system disorder
  • 19 views
  • 01 May, 2022
  • 1 location
Detection and Metabolic Characterization in DOPA PET/CT of Brain Metastases (DOPACER)

metastases but has limitations in therapeutic evaluation, partially offset by PET imaging of amino acid metabolism. Our work aims to compare the performance of PET-DOPA with standard MRI for the

  • 0 views
  • 23 Mar, 2022
  • 2 locations
Contribution of Cerebral 18F-DOPA PET-CT Scan in High-grade Recurrent Gliomas

studies have been performed with 18F-DOPA.( 6-fluoro-[18F]-L-dihydroxyphenylalanine) The question therefore relates to the interest of cerebral 18F-DOPA PET-CT to improve the delineation of the volumes to

  • 0 views
  • 12 Aug, 2021
  • 1 location
Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome

biochemical processes within the abnormal tissue. This protocol tests the ability of [(18)F]-L-3,4-dihydroxyphenylalanine ((18)F-DOPA) PET, Octreoscan and another somatostatin imaging analogue, (68)Ga

ct scan
ectopic acth
hypercortisolism
positron emission tomography
mifepristone
  • 17 views
  • 23 Jul, 2022
  • 1 location